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Abstract This article evaluates the results of portal vein
(PV) stent placement in patients with malignant extrinsic
lesions stenosing or obstructing the PV and causing
symptomatic PV hypertension (PVHT). Fourteen patients
with bile duct cancer (n = 7), pancreatic adenocarcinoma
(n = 4), or another cancer (n = 3) underwent percutaneous
transhepatic portal venous stent placement because of
gastroesophageal or jejunal varices (n = 9), ascites
(n = 7), and/or thrombocytopenia (n = 2). Concurrent
tumoral obstruction of the main bile duct was treated via
the transhepatic route in the same session in four patients.
Changes in portal venous pressure, complications, stent
patency, and survival were evaluated. Mean ± standard
deviation (SD) gradient of portal venous pressure
decreased significantly immediately after stent place-
ment from 11.2 mmHg ± 4.6 to 1.1 mmHg ± 1.0
(P \ 0.00001). Three patients had minor complications,
and one developed a liver abscess. During a mean ± SD
follow-up of 134.4 ± 123.3 days, portal stents remained
patent in 11 patients (78.6%); stent occlusion occurred in 3
patients, 2 of whom had undergone previous major hepa-
tectomy. After stent placement, PVHT symptoms were
relieved in four (57.1%) of seven patients who died (mean
survival, 97 ± 71.2 days), and relieved in six (85.7%) of
seven patients still alive at the end of follow-up (mean
follow-up, 171.7 ± 153.5 days). Stent placement in the PV
is feasible and relatively safe. It helped to relieve PVHT
symptoms in a single session.
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Introduction
Adults develop prehepatic portal vein obstruction
(PHPVO) as a result of various conditions, including
hypercoagulable states and alterations of the venous wall
that result from inflammation or surgery such as hepatec-
tomy or liver transplantation, and in association with
tumors or underlying cirrhosis [1]. Cirrhosis is the leading
cause of portal vein (PV) occlusion, followed closely by
neoplastic disease. Among neoplasms, hepatocellular car-
cinoma (HCC), along with pancreatic or bile duct cancer,
constitute the majority of cases. PHPVO in these cases
occurs as a consequence of direct invasion of the PV by the
tumor, extrinsic compression, periportal fibrosis after sur-
gery or radiotherapy, or a hypercoagulable state that results
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from malignancy. Malignant PHPVO leads to PV hyper-
tension (PVHT) with complications such as esophageal,
gastric, or anorectal varices, hypersplenism, and ascites.
The development of these complications is variable and is
based in particular on the topography of venous obstruction
as well as the possibility for the development of collaterals
vessels around the obstructed PV and portocaval commu-
nications. Variceal hemorrhage and refractory ascites are
the most serious complications. Surgical treatment of these
symptoms generally has poor results, and therefore more
conservative therapies are advocated.
Multiple sessions of endoscopic variceal obliterations or
paracentesis constitute the main therapeutic options. A
single session of treatment with PV stent placement may
constitute an alternative. Since the early 1990s, only a few
case reports or case series addressed stent placement for
treatment of benign PV thrombosis [2], stenosis, or
occlusion due to chronic or acute pancreatitis [3–7],
coagulation disorder [8], or complications related to liver
transplantation or other surgeries [9–13]. Stent placement
to treat malignant PV lesion has been also evaluated [10,
14–22], mainly by Yamakado et al. [14–16], who published
three studies that followed a cohort of patients who pre-
sented with biliary or pancreatic neoplasms, and HCC.
However, little is known about clinical usefulness of PV
stent placement when the portal stenosis is related to a
malignant cause other than HCC, with only 31 patients
reported [10, 14, 15, 17–22].
The purpose of this study was to evaluate results of our
preliminary experience of PV stent placement in patients
with malignant PV lesion, excluding patients with intra-
portal malignant thrombosis arising from HCC.
Methods
Patients
From November 2002 to February 2005, a total of 27
consecutive patients with malignant PV stenosis or
obstruction were depicted with a contrast-enhanced com-
puted tomography (CT) and evaluated for palliative PV
stent placement. The diagnosis of malignant PV invasion
was presumed when a stenosis or obstruction of the portal
system surrounded by tumor was seen. HCC with intra-
portal tumoral extension were not considered for this study.
After a multidisciplinary decision was made for each
patient, 11 of the patients were not considered because
tumoral PV involvement by the cancer was asymptomatic,
and 2 patients were not considered because of their dismal
prognosis and extremely short life expectancy. In all, 14
consecutive symptomatic patients (10 men, 4 women;
mean ± standard deviation age, 63.8 ± 11.3 years; range,
40–77 years) underwent PV stent placement. The clinical
characteristics of these patients are summarized in Table 1.
The diagnosis of primary tumor was established by per-
cutaneous biopsy in seven patients and surgically in the
remaining seven patients. Seven patients had bile duct
cancer, four patients had pancreatic adenocarcinoma, and
three patients had a retroperitoneal endocrine tumor, porta
hepatis adenopathy from a gastric adenocarcinoma, or liver
metastasis from colonic adenocarcinoma. In six patients,
despite primary or secondary tumor resection including
right hepatectomy for three patients, recurrent tumors
invaded the PV. Primary tumors and metastasis involved
the PV in the remaining eight patients.
Table 1 Clinical findings in 14 patients
Patient/Age (years)/Sex Tumor Clinical symptoms Hepatectomy before
portal stent placement
1/72/M Recurrent bile duct adenocarcinoma Refractory ascites, gastroesophageal varices Yes
2/76/M Bile duct adenocarcinoma Ascites, gastroesophageal varices No
3/68/M Recurrent bile duct adenocarcinoma Gastroesophageal varices No
4/48/F Bile duct adenocarcinoma Refractory ascites No
5/72/M Adenopathy from stomach adenocarcinoma Ascites No
6/56/M Retroperitoneal neuroendocrine tumor Gastroesophageal varices No
7/77/F Liver metastasis from colonic adenocarcinoma Ascites, gastroesophageal varices Yes
8/73/M Pancreatic adenocarcinoma Ascites No
9/65/F Recurrent bile duct cancer Gastroesophageal varices No
10/73/M Pancreatic adenocarcinoma Thrombocytopenia, gastroesophageal varices No
11/55/M Recurrent bile duct cancer Ascites, thrombocytopenia Yes
12/40/F Recurrent bile duct cancer Refractory ascites No
13/59/M Pancreatic adenocarcinoma Gastroesophageal varices No
14/59/M Recurrent pancreatic adenocarcinoma Jejunal varices No
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Portal Hypertensive Symptoms
The most common symptom of malignant PHPVO was
gastrointestinal varices, which were observed in nine
patients (64.3%). Five of these patients were actively
bleeding, and up to three sessions of endoscopic sclero-
therapy were necessary. Clinical success was obtained in
four cases of disease. The four other patients with esoph-
ageal (n = 1), gastric (n = 2), or jejunal (n = 1) varices
were not actively bleeding. They did not undergo endo-
scopic treatment, but risk of rupture was assumed for all
of them. Ascites developed in seven patients. Three of
them were categorized as having refractory ascites fol-
lowing the criteria of Arroyo et al. [23]. Thrombocytopenia
was noted for two patients (mean platelet count, 67,000/
lL). Finally, five patients had more than one PVHT
symptom.
Biliary Symptoms
Before PV stent placement, biliary drainage had been
performed for malignant biliary stenosis or occlusion in
five patients with biliary–enteric bypass (n = 2) or biliary
stenting via an antegrade transhepatic route (n = 1) or a
retrograde endoscopic approach (n = 2). At the time of the
procedure of PV stent placement, four patients had jaun-
dice related to a tumoral obstruction of the main bile duct
(n = 3) or to a biliary stent occlusion (n = 1), and one
patient had mild cholestasis most likely related to malig-
nant invasion of an afferent Roux-en-Y afferent limb after
Whipple resection. The remaining four patients were free
of biliary involvement (Table 2).
Procedure of Stent Placement
The nature of the procedure and its possible complications
were fully explained to the patients and their families, and
informed consent was obtained. All procedures were per-
formed by two radiologists (P.C., A.D.), with the patient
under general anesthesia.
For patients with obstruction of the main bile duct, the
procedure began by a transhepatic biliary drainage. First,
cholangiograms were obtained after puncture an intrahe-
patic biliary duct with a 22-gauge echo-tip needle under
sonographic guidance. Second, an intrahepatic biliary duct
was catheterized with a needle catheter under fluoroscopic
and sonographic guidance. The main bile duct occlusion
was crossed with a 0.035-inch stiff hydrophilic guide wire
and dilated with a 10-mm in diameter balloon. Finally, an
uncovered 10-mm-diameter self-expandable metallic stent
was placed, and a 8.5-F internal–external drain was left in
place for 3 to 5 days.
PV stent placement was then started by first puncturing a
second-order portal branch with an 18-gauge percutaneous
cholangiographic needle under sonographic guidance. For
the three patients with refractory ascites and large amount of
fluid around the right liver lobe, a paracentesis was per-
formed first and a transhepatic route via the left lobe was
chosen. An 8-F sheath was inserted into the PV, and a 4-F
Cobra catheter (Terumo, Leuven, Europe) was advanced
Table 2 Characteristics of the procedure
Patient Involved
vessels
Portal venous pressures before
stent placement (mmHg)
Portal venous pressures after
stent placement (mmHg)
Biliary
drainage
Before
stenosis
After
stenosis
Gradient Before
stenosis
After
stenosis
Gradient
1 MPV 30 16 14 20 19 1 Yes
2 LPV, MPV 29 15 14 17 17 0 Yes
3 MPV 24 16 8 18 18 0 No
4 MPV 32 13 19 28 25 3 No (prior)
5 LPV, MPV, SV 12 6 6 8 8 0 Yes
6 MPV 28 18 10 21 20 1 No
7 LPV, MPV 25 20 5 22 22 0 Yes
8 MPV, SMV 24 16 8 25 24 1 No (prior)
9 MPV 21 15 6 21 20 1 No
10 MPV, SMV, SV 17 1 16 17 16 1 No (prior)
11 MPV 31 12 19 22 20 2 No
12 MPV NA NA 11 NA NA 3 No (later)
13 SMV NA NA 10 NA NA 2 No (prior)
14 SMV 14 4 10 6 5 1 No (prior)
MPV, main portal vein; LPV, left portal vein; SV, splenic vein; SMV, superior mesenteric vein; NA, not available
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beyond the stenotic lesions, first in the superior mesenteric
vein (SMV) and second in the splenic vein (SV). Two por-
tograms were performed, each time with a volume of 30 mL
of iodine contrast injected at the rate of 4 to 5 mL/s. PV
occlusion was defined as complete blockade of contrast
medium at the level of the PV lesion even if intrahepatic
portal branches were opacified via collateral veins. After-
ward, PV pressures were measured across the stenotic
lesions by using a device (Eagle 3000, Hellige, Milwaukee,
WI) connected to a monitor (Edwards Lifesciences, Irvine,
CA). A pressure gradient across the stenosis was calculated
and was assumed significant if it was C5 mmHg, as it is the
case for PV stenosis in hepatic transplants [24]. The stenotic
lesions were dilated with a balloon catheter 4 cm in length
and 10 mm in diameter (Powerflex, Cordis endovascular,
Roden, The Netherlands). Uncovered stents (SMART
Control, Cordis, Miami, FL) were placed across the stenosis.
The diameter and length of the stents were determined
according to the diameter and length of involved vessels as
measured during balloon dilation with caution to oversize
the stent diameter by 1–2 mm. Stents used were typically
10–12 mm in diameter and 4–8 cm in length.
After the stents were deployed, portograms and mea-
sures of PV pressures were repeated. An effective
treatment was assumed when control venography showed
rapid flow through the PV with absence of flow in the
previously observed collaterals. A pressure gradient of
3 mmHg or less was considered a technical success as is
the case for treatment of PV stenosis in hepatic transplants
[24]. Finally, the sheath was replaced by a 5-F 20-cm
catheter, and one to three 5-mm in diameter coils (Cook,
Bjaeverskov, Denmark) were placed in the liver
parenchyma tract through this catheter while it was with-
drawn. No anticoagulant therapy or antibiotic therapy were
initiated before, during, or after stent placement.
Follow-up
Complications related to stent placement were evaluated.
Patency of the stents was assessed by performing Doppler
ultrasound or contrast-enhanced CT at the first week and
every 3 months thereafter, or at any time if the symptoms
of PVHT recurred or were judged not to have improved.
Endoscopic control of patients with varices was scheduled
7 days after PV stent placement and every 6 months
thereafter. The clinical courses after PV stent placement
and the causes of death were studied from clinical records
until April 1, 2005.
Statistical Analyses
The data were expressed as mean ± standard deviation.
Differences in portal pressures measured before and after
stent placement were compared by performing the paired
Student t-test. A P value of less than 0.05 was considered
to indicate a statistically significant difference.
Results
Stent Placement
The results of PV stent placement are summarized in
Tables 2 and 3. Fifteen stenosis and six occlusions were
Table 3 Clinical courses after portal venous stent placement
Patient Complications Resolution
of symptoms
Patency/interval
(days)
Survival
(days)
Cause of death
1 No Yesa Occlusion/83 178 Cancer
2 No Yes Patent/122 122 Cancer
3 No Yes Patent/434 434 Alive
4 Minor perihepatic hematoma Yes Patent/32 32 Tumoral gastrointestinal bleeding
5 Biological pancreatitis Yes Patent/182 182 Cancer
6 No Yes Patent/342 342 Alive
7 No No Patent/14 14 Cancer
8 Minor portal dissection Yes Patent/137 137 Alive
9 Liver abscess Yes Patent/31 31 Cancer
10 No Yes Patent/92 92 Alive
11 No No Occlusion/2 71 Alive
12 No Yesa Occlusion/113 120 Cancer
13 No Yes Patent/96 96 Alive
14 No Yes Patent/30 30 Alive
a Improvement until occlusion of the portal stent
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found, involving the main PV (n = 12) (Figs. 1 and 2), the
SMV (n = 4), the left PV (n = 3) (Fig. 2), or the SV
(n = 2). All lesions were successfully catheterized and
dilated. Two patients had an occlusion of both the main PV
and the distal part of the SV, and one of them also had an
Fig. 1 A 55-year-old man who underwent a right hepatectomy
15 months ago for bile duct cancer (patient 11). Recurrent bile duct
cancer responsible for ascites and thrombocytopenia. A Initial
portography showing a stenosis of the distal part of the main PV
leading to a 22 mmHg portal venous pressure gradient. B Repeated
portography after portal venous stent placement and showing massive
opacification of intrahepatic portal branches. The final portal venous
pressure gradient was almost normalized (2 mmHg), but stent
occlusion occurred 2 days later
Fig. 2 A 77-year-old woman with liver metastasis from colonic
adenocarcinoma leading to biliary malignant obstruction treated via
the retrograde endoscopic route 3 months ago (patient 7). Current
esophageal varices bleeding and ascites in relation to a malignant
venous portal stenosis. A Contrast-enhanced computed tomography
showing liver hilar metastasis inducing recurrent intrahepatic biliary
dilation, stenosis of the main PV, and ascites. B Initial superior
mesenteric venography showing the stenosis of the main PV
extending to the left PV and esophageal varices. C Repeated superior
mesenteric venography after portal venous stent placement with no
residual filling of periesophageal venous collaterals. Ascites had not
decreased by the time of the patient’s death 14 days later
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occlusion of the distal part of the SMV. In these two
patients, a stent was initially placed from the distal part of
the SMV to the distal part of the main PV, and a second
stent was placed through the first one to treat the SV
occlusion. The remaining patients had a single stent in the
main PV or the SMV (Figs. 1 and 2). Even though it was
technically feasible with a single transhepatic approach, we
performed any stent placement for associated left intrahe-
patic PV stenosis by a second left transhepatic approach.
In all patients, repeated portograms showed an efficient
treatment. After stent placement, the mean PV pressure
decreased significantly (P \ 0.001), from 23.9 mmHg ±
6.7 (range, 12–32 mmHg) to 18.7 mmHg ± 6.3 (range,
6–28 mmHg), and the mean intrahepatic portal pressure
increased significantly (P \ 0.01), from 12.7 mmHg ± 5.9
(range, 4–20 mmHg) to 17.8 mmHg ± 5.9 (range,
5–25 mmHg). As a result, the mean gradient of portal
venous pressure was almost normalized and significantly
decreased (P \ 0.00001) from 11.2 mmHg ± 4.6 (range,
5–19 mmHg) to 1.1 mmHg ± 1.0 (range, 0–3 mmHg)
after portal venous stent placement.
Biliary Drainage
Biliary drainage added in mean 33 ± 7.7 minutes (range,
24–42 minutes) to the time procedure. In all the patients,
drainage was successfully performed in a single session,
and a complete resolution of cholestasis was obtained.
Complications
Pain related to the puncture site was not prospectively
evaluated because it was always minor and quickly sub-
sided when treated with nonnarcotic analgesics.
Three patients had minor complications that did not
require specific treatment. One patient developed a
2 9 3 cm subcapsular hematoma at the puncture site while
the sheath was withdrawn before embolization of the liver
parenchymal tract. Another patient developed a minor
dissection of the main PV within 2 cm of length obstruc-
tion. The last patient, who had been treated for PV and
main bile duct stenosis, developed a transient mild increase
in biological pancreatic enzymes without any clinical
symptoms.
One major complication occurred in a patient with a
slight intrahepatic biliary dilation and a minor biological
cholestasis. This patient did not undergo biliary drainage at
the time of PV stenting and developed a liver abscess in the
vicinity the coils left in the liver. This abscess was drained
percutaneously for 5 days, and the patient died 26 days
later for reasons related to his cancer and without any
evidence of residual or recurrent sepsis.
Stent Patency, Evolution of Symptoms, and Survival
During the mean follow-up period of 134.4 ± 123.3 days
(range, 30–434 days), PV stents remained patent in 11
patients (78.6%). Stent occlusion was suspected clinically
and confirmed at Doppler ultrasound in two patients who
developed sudden abdominal pain after 83 and 113 days,
and was depicted at the first ultrasound control in a third
asymptomatic patient. These three patients had been trea-
ted with PV stent placement for a stenosis (n = 2) or
occlusion (n = 1) of the main PV. Two patients had had
right hepatectomy 13 and 15 months before stent place-
ment. In the last patient, contrast-enhanced CT control was
consistent with a stent occlusion related to tumor ingrowth
and overgrowth.
After stent placement, initial resolution of PVHT
symptoms were noted for 12 patients (85.7%) without any
residual varices at endoscopic control, ascites on imaging,
or thrombocytopenia on laboratory testing. In one patient
who had an early occlusion of the portal stent, ascites
became refractory. In the last patient who died 14 days
later in relation to his cancer, the ascites was not modified
even though the stent remained patent, and gastroesopha-
geal varices were not checked by endoscopy.
At the end of the follow-up, 10 patients (71.4%) were
free of PVHT symptoms. Seven patients had died at
97.0 ± 71.2 days (range, 14–182 days) after stent place-
ment, mainly as a result of cancer progression (n = 6). One
patient died as a result of a tumoral gastrointestinal
bleeding. Four patients (57.1%) remained asymptomatic
until their death. Six (85.7%) of the seven surviving
patients were free of symptoms 171.7 ± 153.5 days
(range, 30–434 days) after stent placement.
Discussion
Procedures
PV stent placement has been described with a surgical
approach via an ileal or jejunal vein [3, 13, 21, 24, 25] or a
transjugular intrahepatic portosystemic shunt–type
approach [4, 11, 18]. Nevertheless, as in our study, a
transhepatic route has been most often used in the past with
a very low rate of hemorrhagic complications [5, 6, 14–17,
20–22, 26]. As previously described in a published case
report [27], we have had one minor subcapsular hematoma.
Hemobilia related to a pseudoaneurysm of the hepatic
artery has also been reported [15]. To prevent intraperito-
neal hemorrhage, it is crucial to embolize the liver
parenchymal tract when the sheath is withdrawn. Gelatin
sponges [6, 14–16], biological tissue adhesive [17], and
coils [4, 27] have all been used. We use coils instead of
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gelatin sponges because their delivery is more precise and
is not affected by potential massive bleeding through the
liver tract. Although massive ascites also increases the
hemorrhagic risk, it does not constitute an absolute con-
traindication to a transhepatic route. In this situation, a
large paracentesis should first be performed with a left
hepatic lobe approach used for stent placement because the
amount of fluid around it is generally less than around the
right lobe.
Synchronous biliary dilation secondary to biliary or
afferent loop tumoral involvement has been described only
rarely [14, 22]. Nevertheless, in our study, this situation
was not unusual, occurring in five patients. Biliary drainage
can be safely performed in the same session, adding only
few minutes to the procedure. It seems that such a drainage
is more important for the prevention of liver abscesses than
it is for the prevention of hemobilia. Indeed, one case of
liver abscess has been reported [14], and we have had the
same experience with one of our patients; both cases
involved patients who had undergone undrained intrahe-
patic biliary dilation with cholestasis.
Occlusion of Stents
To our knowledge, only one study has evaluated factors
affecting patency of PV stents [15]. This particular study
involved two groups of patients: one group of 17 patients
with pancreatic or bile duct tumors stenosing or obstructing
main PV, and the other group consisting of 23 patients with
HCC extending from intrahepatic veins to main PV. They
found a stent occlusion rate of 40% with a mean follow-up
period of 11.9 months. Multivariate analysis demonstrated
three factors significantly associated with a higher proba-
bility of stent occlusion: splanchnic vein involvement,
cirrhotic patients classified Child-Pugh class C, and
obstruction of the portal venous system. The authors con-
cluded that patients with these characteristics should not be
treated with stents. Pathophysiology of PV occlusion and
clinical outcome for the two groups of patients included
were quite different and this point constitute a major
drawback of this study. Nevertheless, these results seem to
indicate that there is a strong relationship between stent
occlusion and a variety of causes reducing blood flow
through the stented vessel, this relation being yet demon-
strated experimentally with an animal model [24]. Indeed,
liver dysfunction is correlated with a reduction of portal
venous blood flow.
Splanchnic involvement can also reduce the mesenteric
blood flow: splanchnic veins have a smaller diameter than
the main PV, and adjacent arteries can be involved at the
same time. We observed that previous major hepatectomy
was associated with a higher rate of stent occlusion. This
could possibly be explained by a reduction in portal blood
flow after surgery [28]. However the number of cases in
our study does not allow for a definitive conclusion. This
factor has not been evaluated by Yamakado et al. [15] and
was not associated with stent occlusion in two observations
found in the literature with previous hepatectomy and stent
patency at 3-month and 19-month follow-up [10, 19].
On the other hand, to prevent stent thrombosis, Yama-
kado et al. [14–16] presume that anticoagulant therapy and/
or antiplatelet therapy are essential because the stent itself
exhibits thrombogenicity and because stents are not cov-
ered by neointima when they are implanted in a PV
invaded by neoplasm [14, 15, 29]. In most published
observations of venous stent placement for benign or
malignant portal lesions, we can find utilization of such
therapies without any standardized protocol [4, 6, 8, 11, 12,
17, 28]. However, there is a lack of randomized study to
assess the exact usefulness of anticoagulation in case of
portal stenting, and despite anticoagulation, half of cases of
stent occlusion described by Yamakado et al. [15] were
related to thrombus formation. As others [3, 5, 9, 10, 19,
20], we did not administer anticoagulants, and in 91.7% of
the patients who had not previously undergone hepatec-
tomy, stents remained patent, with a mean follow-up time
of 137.4 days. We think that indication to anticoagulation
should be weighted against the risk of gastrointestinal
bleeding. In our study, more than half of the patients
underwent PV stent placement for hemorrhagic varices,
and one woman died in relation to tumoral and hemor-
rhagic gut ulcerations. Anticoagulation can be proposed
when the placement of the portal stent allows a significant
decrease in the flow or even embolization of dangerous
varices as well as in situations such as when reduced flow
through the stented vessels is expected or when an under-
lying hypercoagulable state is demonstrated [1].
Indications for Portal Venous Stent Placement
he indication for PV stent placement remains an individual
decision that takes into consideration patient status, severity
of stenosis, and the natural course of the disease [17]. PV
stent placement can be one of the useful combined therapies
in patients with symptomatic malignant PV stenosis or
occlusion [14]. Except in patients with conditions predis-
posing to stent occlusion, it can allow relief of PVHT
symptoms in a single session until patient’s death [14–16,
20]. In our study, 71.4% of patients were free of symptoms
during a mean follow-up of 134.4 days (range, 30–
434 days). Among symptoms developing in a neoplastic
context, ascites can be related to PVHT and/or peritoneal
carcinosis. For one of our patients with advanced neoplastic
status, relief of ascites was not observed in a follow-up of
14 days, despite initial technical success, normalization of
PV gradient pressure, and stent patency. This failure may
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have been the result of peritoneal carcinomatosis because it
occurs in roughly two-thirds of patients with malignancy-
related ascites [30]. Although challenging to detect with
imaging, cytologic analysis of ascites is 100% sensitive
[30]. As a result, if the etiology of ascites is unclear, cyto-
logic analysis of peritoneal liquid should be performed
before the decision of portal venous stent placement.
Even though veins occlude earlier than arteries as a
result of tumor compression, venous lesions are often
asymptomatic because of abundant collateralization. In our
experience, this situation is observed in approximately half
of patients with malignant venous stenosis or occlusion,
especially in cases of pancreatic cancer. PV lesions related
to bile duct cancer seem to be more frequently symptom-
atic because half of the patients included in our study had
such primary or recurrent cancer. Decreased venous col-
lateralization resulting from malignant invasion of epi- and
paracholedochal venous plexus could be an explanation.
For patients who develop asymptomatic PV stenosis or
occlusion, indication of venous stent placement remains
unclear. Given the risk of portal stent occlusion, these
patients should not undergo stent placement and must have
a careful follow-up in order to intervene early if PVHT
symptoms occur.
Study Limitations
As in the case of other published case series [14–16, 20],
the main limitation of the present study is the small number
of patients, which limits statistical analysis of factors
affecting stent patency. The small number of patients
having had prior major hepatectomy does not allow us to
determine the role of this factor in the occurrence of PV
stent occlusion. In addition, the cause of stent occlusion
was not demonstrated by pathologic examination. Finally,
this retrospective study does not assess objectively post-
procedural minor complications such as pain or
improvement in the patient’s quality of life.
In conclusion, radiologists should keep in mind the
option of PV stent placement during imaging follow-up of
oncologic patients prone to develop malignant PV stenosis
or occlusion, especially those with a bile duct cancer. This
single-step therapeutic option most often constitutes an
efficient treatment of symptoms related to PVHT.
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